Barbara Gayle Duncan - Jun 16, 2023 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role: Director
Signature: /s/ Andrea Corcoran, as Attorney-in-Fact for Barbara Gayle Duncan
Stock symbol: AVIR
Transactions as of: Jun 16, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/21/2023, 04:05 PM
Previous filing: Jun 14, 2023
Next filing: Feb 26, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVIR	Restricted Stock Units	Award	$0	+33.2K		$0.00	33.2K	Jun 16, 2023	Common Stock	33.2K		Direct	F1, F2
transaction	AVIR	Stock Option (Right to Buy)	Award	$0	+46.8K		$0.00	46.8K	Jun 16, 2023	Common Stock	46.8K	$4.12	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
F3	The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 16, 2023, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.